论文部分内容阅读
蛋白络氨酸激酶抑制剂作为目前治疗效果明显而且应用前景广阔的抗肿瘤药物备受青睐。本文以近5年的文献为主要参考,对已经上市的和处于研究阶段的脲类酪氨酸激酶抑制剂进行了综述。
Protein tyrosine kinase inhibitors as the current treatment effect is obvious and broad prospects for the application of anti-tumor drugs favored. In this paper, the last five years as the main reference of the literature, has been listed and in the research stage urea tyrosine kinase inhibitors were reviewed.